Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Συντάκτης [ Τίτλος![(Desc)](https://www.med.auth.gr/sites/all/modules/biblio/misc/arrow-desc.png)
Φίλτρα: Συντάκτης is Athyros, Vasilios G [Clear All Filters]
Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low..
Curr Med Res Opin. 30(1), 57-8.
(2014). Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients..
Open Cardiovasc Med J. 1, 8-14.
(2007). Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention..
Curr Vasc Pharmacol. 7(3), 264-6.
(2009). Statins and heart failure..
J Am Coll Cardiol. 55(15), 1644-5; author reply 1646.
(2010). Statins and nonalcoholic fatty liver disease: a bright future?.
Expert Opin Investig Drugs. 22(9), 1089-93.
(2013). Statins and non-alcoholic steatohepatitis..
J Hepatol. 64(1), 241-2.
(2016). Statins and regression of coronary atherosclerosis..
JAMA. 297(20), 2197; author reply 2197.
(2007). Statins and renal function. Is the compound and dose making a difference?.
Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
(2007). Statins and Type 2 Diabetes Mellitus: An Update After 1 Year..
Curr Pharm Des. 22(18), 2723-5.
(2016). Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?.
Expert Opin Pharmacother. 16(10), 1449-61.
(2015). Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures..
Curr Drug Targets. 8(8), 942-51.
(2007). Statins for the prevention of first or recurrent stroke..
Curr Vasc Pharmacol. 6(2), 124-33.
(2008). Subclinical Cushing's syndrome and cardiovascular disease..
Lancet Diabetes Endocrinol. 2(5), 361.
(2014). Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?.
J Hypertens. 36(3), 701.
(2018). Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?.
Curr Vasc Pharmacol. 14(1), 88-97.
(2016). Targeting vascular risk in patients with metabolic syndrome but without diabetes..
Metabolism. 54(8), 1065-74.
(2005). Therapeutic options for statin-intolerant patients..
Curr Med Res Opin. 28(3), 345-9.
(2012). Therapy: Caloric and fat intake in statin users..
Nat Rev Endocrinol. 10(8), 450-1.
(2014). Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?.
Open Cardiovasc Med J. 6, 28-32.
(2012). Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?.
Arch Med Sci. 7(6), 1067-75.
(2011). Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study..
Open Cardiovasc Med J. 10, 64-8.
(2016). Is there an association between inflammatory bowel diseases and carotid intima-media thickness? Preliminary data..
Angiology. 65(6), 543-50.
(2014). Is there any association between adiponectin gene polymorphisms and cardiovascular disease?.
Angiology. 64(4), 253-6.
(2013). Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk..
Angiology. 63(1), 9-11.
(2012). To switch (statins) or not to switch? That is the question..
Expert Opin Pharmacother. 11(18), 2943-6.
(2010).